Achieve Life Sciences (NASDAQ: ACHV) reported Q4 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32).

"With over 34 million smokers and nearly 11 million vape and e-cigarette users in the United States alone, the nicotine addiction epidemic continues to be a major public health crisis that Achieve is exclusively focused on addressing through the development of cytisinicline." commented Rick Stewart, Chairman and Chief Executive Officer of Achieve. "Our key priorities in the coming months are to initiate the ORCA-2 Phase 3 clinical trial in smokers and secure non-dilutive financing to evaluate cytisinicline specifically in the growing population of vape users."

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.